ReviewFrontiers in pharmacology2025
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-World Luspatercept Evidence in Myelodysplastic Neoplasms: A Systematic Review and Bayesian Meta-Analysis.Hematological oncology · 2026Pooled it
- Effectiveness of live-attenuated and inactivated influenza vaccines against influenza in 2-17-y-old children, United States, 2022-2025.Human vaccines & immunotherapeutics · 2026Article
- Choosing real-world data for clinical and epidemiological research: methodological lessons from NHIRD and TriNetX-A narrative review.Annals of medicine · 2026Review
- Prescribing Trajectories in Type 2 Diabetes in the United States, 2019-2024.Diabetes, obesity & metabolism · 2026Article
- The Psychiatric Comorbidities in Adolescents With Atopic Dermatitis: A Real-World Study of Propensity-Matched Cohorts.International journal of dermatology · 2026Article
- Long-term cardiovascular risks in patients with hypertensive disorders of pregnancy treated with nifedipine or labetalol.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Implementation science and the clinical trial workforce: A national needs assessment of training and practice.Contemporary clinical trials communications · 2026Article
- Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study.Lancet regional health. Americas · 2026Article
- Mechanical Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary Embolism: A Risk-Stratified, Propensity Score-Matched Analysis.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Mildly Elevated Preoperative Inflammatory Markers and Postoperative Complications Following Total Knee Arthroplasty: A Propensity-Matched Cohort Analysis.Arthroplasty today · 2026Article
- Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men.EBioMedicine · 2026Article
- Early Computed Tomography Imaging and Clinical Outcomes in Hospitalized Patients with Acute Diverticulitis: A Propensity-Matched Multicenter Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Association of obstructive sleep apnea and continuous positive airway pressure on risk of corneal ulceration and surgical interventions.International ophthalmology · 2026Article
- Mapping TriNetX-Based Real-World Evidence Publications by Clinical Domain and Study Purpose, 2018-2025: A Bibliometric Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Prevalence, Timing and Mutual Relationships of Acute and Chronic Respiratory Failure in People with Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2026Article
- Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.Acta dermato-venereologica · 2026Article
- Cardiovascular Outcomes Associated with Romosozumab Versus Denosumab in Chronic Kidney Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.Hepatology international · 2026Article
- Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer.JAMA network open · 2026Article
- Achilles Tendinopathy: Comorbidity Profile and Incidence From the TriNetX Network.Medical research archives · 2026Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy and safety of both pharmacological and non-pharmacological interventions. However, while they are designed to control confounders and ensure internal validity, their usually stringent inclusion and exclusion criteria often limit the generalizability of findings to broader patient populations. Moreover, RCTs are resource-intensive, frequently underpowered to detect rare adverse events, and sometimes narrowly focused due to their highly controlled environments. In contrast, real-world data (RWD), typically derived from electronic health records (EHRs) and claims databases, offers a valuable counterpart for answering research questions that may be impractical to address through RCTs. Recognizing this, the US Food and Drug Administration (FDA) has increasingly relied on real-world evidence (RWE) from RWD to support regulatory decisions and post-market surveillance. Platforms like TriNetX, that leverage large-scale RWD, facilitate collaborations between academia, industry, and healthcare organizations, and constitute an in-depth tool for retrieval and analysis of RWD. TriNetX's federated network architecture allows real-time, privacy-compliant data access, significantly enhancing the ability to conduct retrospective studies and refine clinical trial designs. With access to currently over 150 million EHRs, TriNetX has proven particularly effective in filling gaps left by RCTs, especially in the context of rare diseases, rare endpoints, and diverse patient populations. As the role of RWD in healthcare continues to expand, TriNetX stands out as a critical tool that complements traditional clinical trials, bridging the gap between controlled research environments and real-world practice. This review provides a comprehensive analysis of the methodologies and applications of the TriNetX platform, highlighting its potential contribution to advance patient care and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.